Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PA-CSC

Financiado

Cerrado

Molecular characterization and targeted elimination of metastatic pancreatic can...

Molecular characterization and targeted elimination of metastatic pancreatic cancer stem cells Pancreatic adenocarcinoma is the deadliest solid cancer and currently the fourth most frequent cause for cancer related deaths. Over the past decades, there has hardly been any substantial therapeutic progress regarding clinical e... ver más

31/12/2014

FUNDACION SECTOR P...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACION SECTOR PUBLICO EST...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EPC-TM-NET Targeting the tumour microenvironment to improve pancreatic... 4M€ Cerrado

PACA-MET Genome wide surveys and functional analysis of pancreatic ca... 2M€ Cerrado

PID2021-124106OB-I00 TERAPIAS PERSONALIZADAS EN CANCER DE PANCREAS 508K€ Cerrado

PDA_TGFb TGF beta mediated crosstalk between cancer stem cells and... 180K€ Cerrado

SAF2013-42946-R CELULAS MADRE TUMORALES EN SARCOMAS: BUSQUEDA DE NUEVAS DIAN... 145K€ Cerrado

PDASwITch Super enhancer modules controlling plasticity and response t... 161K€ Cerrado

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pancreatic adenocarcinoma is the deadliest solid cancer and currently the fourth most frequent cause for cancer related deaths. Over the past decades, there has hardly been any substantial therapeutic progress regarding clinical endpoints. New hope has now been generated by the re-emerging cancer stem cell (CSC) concept. We have identified and characterized pancreatic CSC in the context of tumour growth, metastasis, and resistance to chemotherapy. To eventually be able to develop a targeted therapy for eliminating CSCs as the root of the tumour, we will perform comparative functional and genomic analyses of the identified, highly purified human CSC populations, their more differentiated progenies, normal tissue resident stem cells, and hematopoietic stem cells. For these analyses, we are also focusing on their demonstrated resistance of CSC to chemotherapy as well as their invasive properties and tumour-initiating capacity as demonstrated in our orthotopic mouse models. Subsequent functional characterization of newly identified genes regarding their biological function for tumour angiogenesis, invasiveness, and metastasis will be carried out. Moreover, it is similarly important to investigate in parallel the origin of CSCs, which may aid us to develop new therapeutic strategies to prevent transformation of tissue-resident stem cells. The role of risk factors that have been associated with the development of pancreatic cancer, namely smoking and chronic pancreatitis will be investigated in this context. Together, the above experiments will generate important clues how CSCs circumvent the physiological regulatory elements of stem cell functionality and, even more importantly, how these cells escape the response to standard cancer therapy. Eventually, these new insights may allow us to develop novel targeted and multimodal treatment modalities for the successful elimination of these cells as the previously unrecognized root of the tumour.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores